UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

# NOTICE OF ALLOWANCE AND FEE(S) DUE

7590

03/20/2008

Kathy Smith Dias, Esq. HESLIN ROTHENBERG FARLEY & MESITI P.C. 5 Columbia Circle Albany, NY 12203-5160 EXAMINER

GEBREYESUS, KAGNEW H

ART UNIT PAPER NUMBER

1656

DATE MAILED: 03/20/2008

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/511.756	05/25/2005	Andreas Bergmann	2582.017	4938

10/511,756 05/25/2005 Andreas Bergmann 2582.017

TITLE OF INVENTION: USES OF CARBAMOYL PHOSPHATE SYNTHETASE FOR THE DIAGNOSIS OF INFLAMMATORY DISEASES AND SEPSIS

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1440	\$300	\$0	\$1740	06/20/2008

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

#### HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

### PART B - FEE(S) TRANSMITTAL

### Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or <u>Fax</u> (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where ar in m

maintenance fee notifica	tions.			_			correspondence address as trate "FEE ADDRESS" for or domestic mailings of the
CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)  7590 03/20/2008				Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.			
Wadaa Cadda D	_	Ce	rtificat	e of Mailing or Trans	mission		
Kathy Smith Dias, Esq. HESLIN ROTHENBERG FARLEY & MESITI P.C. 5 Columbia Circle			I S a tu	hereby certify that to tates Postal Service ddressed to the Ma ransmitted to the USI	his Fee( with sul il Stop PTO (57	s) Transmittal is being fficient postage for first ISSUE FEE address (1) 273-2885, on the d	g deposited with the United st class mail in an envelope above, or being facsimile ate indicated below.
Albany, NY 122	203-5160		Г				(Depositor's name)
							(Signature)
							(Date)
APPLICATION NO.	FILING DATE		FIRST NAMED INVENT	OR	ATTC	PRNEY DOCKET NO.	CONFIRMATION NO.
10/511,756	05/25/2005	· ·	Andreas Bergmann		1	2582.017	4938
TITLE OF INVENTION SEPSIS	N: USES OF CARBAM	IOYL PHOSPHATE SY	YNTHETASE FOR TH	E DIAGNOSIS OF	INFLA	MMATORY DISEAS	ES AND
APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DU	E PREV. PAID ISSU	JE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1440	\$300	\$0		\$1740	06/20/2008
EXAM	IINER	ART UNIT	CLASS-SUBCLASS				
GEBREYESUS	S, KAGNEW H	1656	435-400000				
☐ "Fee Address" ind	oondence address (or Cha B/122) attached. lication (or "Fee Address )2 or more recent) attach	registered attorney or agent) and the names of up to					
PLEASE NOTE: Un	less an assignee is ident th in 37 CFR 3.11. Comp	A TO BE PRINTED ON ified below, no assignee pletion of this form is NO	data will appear on the T a substitute for filing (B) RESIDENCE: (CI	e patent. If an assig an assignment. TY and STATE OR	COUNT	TRY)	ocument has been filed for
Please check the appropr	riate assignee category or	categories (will not be pa	rinted on the patent):	☐ Individual ☐ C	Corporat	ion or other private gro	oup entity  Government
4a. The following fee(s)	are submitted:	41	b. Payment of Fee(s): (P		ny pre	viously paid issue fee	shown above)
Issue Fee	No small entity discount p	parmittad)	A check is enclose Payment by credit		Q is att	achad	
	# of Copies		The Director is her		roe the	required fee(s) any de	ficiency, or credit any n extra copy of this form).
5. Change in Entity Sta	`	· · · · · · · · · · · · · · · · · · ·	_				
	ns SMALL ENTITY state and Publication Fee (if reco					TITY status. See 37 CI	ne assignee or other party in
interest as shown by the	records of the United Sta	ites Patent and Trademark	COffice.	upp, w.r.e			
Authorized Signature				Date			
				-			
This collection of inform an application. Confiden submitting the complete this form and/or suggest Box 1450, Alexandria, V Alexandria, Virginia 223	tiality is governed by 35 d application form to the ions for reducing this bu. Virginia 22313-1450. DC	FR 1.311. The informatic U.S.C. 122 and 37 CFR USPTO. Time will vary rden, should be sent to the O NOT SEND FEES OR	on is required to obtain 1.14. This collection is 7 depending upon the in the COMPLETED FORMS	or retain a benefit by estimated to take 12 dividual case. Any c icer, U.S. Patent and TO THIS ADDRES	the pub minute ommen I Trader S. SEN	lic which is to file (and s to complete, includin ts on the amount of tir mark Office, U.S. Depa D TO: Commissioner	by the USPTO to process) g gathering, preparing, and me you require to complete artment of Commerce, P.O. for Patents, P.O. Box 1450,

PTOL-85 (Rev. 08/07) Approved for use through 08/31/2010.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/511,756	05/25/2005	Andreas Bergmann	2582.017	4938	
75	90 03/20/2008		EXAM	INER	
Kathy Smith Dias, Esq.			GEBREYESUS, KAGNEW H		
HESLIN ROTHEN	NBERG FARLEY & M	ESITI P.C.	ART UNIT	PAPER NUMBER	
5 Columbia Circle Albany, NY 12203-5160			1656 DATE MAILED: 03/20/200	8	

## **Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)**

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 102 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 102 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

	Application No.	Applicant(s)
	10/511,756	BERGMANN ET AL.
Notice of Allowability	Examiner	Art Unit
	KAGNEW H. GEBREYESUS	1656
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI	(OR REMAINS) CLOSED in this a or other appropriate communication IGHTS. This application is subject	pplication. If not included on will be mailed in due course. <b>THIS</b>
1. This communication is responsive to an IDS filed on 2/27/0	<u>08</u> .	
2. 🔀 The allowed claim(s) is/are <u>18,19,21-24 and 26-31</u> .		
<ul> <li>3.  Acknowledgment is made of a claim for foreign priority ur</li> <li>a)  All b)  Some* c)  None of the:</li> <li>1.  Certified copies of the priority documents have</li> <li>2.  Certified copies of the priority documents have</li> </ul>	e been received.	
3. Copies of the certified copies of the priority do	cuments have been received in thi	s national stage application from the
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  4.   A SUBSTITUTE OATH OR DECLARATION must be subm	MENT of this application.  itted. Note the attached EXAMINE	R'S AMENDMENT or NOTICE OF
INFORMAL PATENT APPLICATION (PTO-152) which give		ration is deficient.
5. CORRECTED DRAWINGS (as "replacement sheets") mus		
(a) ☐ including changes required by the Notice of Draftspers	<del>-</del> ·	D-948) attached
1)  hereto or 2)  to Paper No./Mail Date		0.5%
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date	s Amendment / Comment or in the	Office action of
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t		
6. DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT		
Attachment(s)	5 Notice of Informal	Potent Application
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Dotice of Draftperson's Patent Drawing Review (PTO-948)</li> </ol>	<ol> <li>5. ☐ Notice of Informal</li> <li>6. ☐ Interview Summal</li> </ol>	
3. ☑ Information Disclosure Statements (PTO/SB/08),	0. ☐ Interview Summal Paper No./Mail D 7. ☑ Examiner's Amen	ate
Paper No./Mail Date 2/27/08		
<ol> <li>Examiner's Comment Regarding Requirement for Deposit of Biological Material</li> </ol>		nent of Reasons for Allowance
	9.	

Application/Control Number: 10/511,756 Page 2

Art Unit: 1652

### **DETAILED ACTION**

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on February 27, 2008 has been entered.

#### Information Disclosure Statement

The information disclosure statement (IDS) submitted February 27, 2008 was filed after the mailing date of the Notice of Allowance on November 28, 2008. The information disclosure contains several Patent Applications pertaining to the use of various molecules in the diagnosis of sepsis.

The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement for which a copy of the Patent Applications has been submitted in this application has been considered as shown by the Examiners signature next to each reference.

### REASON FOR REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

Application/Control Number: 10/511,756 Page 3

Art Unit: 1652

The closest prior art disclosure from the newly submitted information disclosure statement is the disclosure in Application US20050239150 A1 (Bergmann Andreas). Bergmann teaches a method for the early diagnosis, the prognosis and the assessment of the severity and for the therapy-accompanying assessment of the course of sepsis and sepsis-like systemic infections based on the presence and/or amount of anti-asialo-GM1 antibodies(anti-AGM1 antibodies) and antibodies cross-reacting therewith in a biological fluid of a patient or sepsis risk. Furthermore Bergmann teaches that at least one other parameter selected from the group consisting of the proteins procalcitonin, CA 125, CA 19-9, S100B, S100A proteins, LASP-1, soluble cytokeratin fragments, in particular CYFRA 21, TPS and/or soluble cytokeratin-1 fragments (sCY1 F), the peptides inflammin and CHP, peptide prohormones, glycine N-acyltransferase (GNAT), carbamoylphosphate synthetase 1 (CPS 1) and the C-reactive protein (CRP) or fragments thereof is determined as part of the multiparameter determination.

The instant invention is drawn to a method for the diagnosis of sepsis in a human patient based on the presence and amount of <a href="https://human.carbamoyl.phosphate.synthetase">human.carbamoyl.phosphate.synthetase</a>
<a href="https://human.carbamoyl.phosphate.synthetase">1(CPS 1) (SEQ ID NO: 6) in human blood, plasma, or serum using an immunodiagnostic assay.</a>
Furthermore the instant Application also teaches a multi-parameter determination, wherein at least one other sepsis marker is chosen from procalcitonin, cancer antigen 19-9 (CA 19-9), cancer antigen 125 (CA 125), protein S 100B, protein S 100 A, soluble cytokeratin fragments, inflammin peptide, calcitonin-homologue peptide (CHP), the LIM, actin, and SH3 domain protein-1 (LASP-1), peptide prohormone immunoreactivity, and C-reactive protein (CRP).

The instant Application doesn't include anti-asialo-GM1 antibodies (anti-AGM1 antibodies), which is the preferred embodiment in US20050239150 A1 (Bergmann).

Therefore the instant invention is patentably distinct and free of the prior art.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

**Conclusion:** Claims 18, 19, 21-24, and 26-31 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAGNEW H. GEBREYESUS whose telephone number is (571)272-2937. The examiner can normally be reached on 8:30am-5:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen Kerr Bragdon can be reached on 571-272-0931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/511,756 Page 5

Art Unit: 1652

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Kagnew H Gebreyesus PhD/ Examiner, Art Unit 1656 3/15/08

> /Robert B Mondesi/ Primary Examiner, Art Unit 1652

Application Number

Application/Control No.	Applicant(s)/Patent under Reexamination		
10/511,756	BERGMANN ET	AL.	
Examiner	Art Unit		
KAGNEW H. GEBREYESUS	1656		

U.S. Patent and Trademark Office Part of Paper No. 20080315